Anti-mCD20-mIgG2a InvivoFit™ is a mouse anti-mouse monoclonal antibody (mAb) featuring the variable region of the previously described anti-mCD20 18B12 clone . Using recombinant technology, the original 18B12 murine IgG1 constant region has been replaced with a murine IgG2a format which mediates potent cytotoxic functions .
CD20 is a cell surface protein mainly expressed by resting and activated B lymphocytes, but not plasma cells . CD20 is also expressed by most malignant B cells, which makes it an ideal target for antibody-based immunotherapies against lymphoid malignancies [3-6].
The anti-mCD20 18B12 mAb is commonly used for in vivo depletion of the CD20+ B cell population to study the role of B cells in various immune responses, including auto-immune or tumoral contexts [1, 7].
Key features of Anti-mCD20-mIgG2a InvivoFit™:
- Derives from the 18B12 clone, mouse IgG1, κ
- Features the mIgG2a isotype (constant region)
- Guaranteed sterile, endotoxin level < 1 EU/mg
- Suitable for parental delivery in mice (azide-free)
- Low aggregation < 5%
- Produced in animal-free facilities and defined media
Anti-mCD20-mIgG2a InvivoFit™ is produced in Chinese hamster ovary (CHO) cells, purified by affinity chromatography with protein A, and provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo studies. The specific binding of this mAb to mCD20 has been confirmed by FACS (see Figure).
- Ahuja A. et al., 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179(5):3351-3361.
- Nimmerjahn F. & Ravetch J.V., 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 310(5753):1510-2.
- Uchida J. et al., 2004. Mouse CD20 expression and function Int Immunol. 16(1):119-29.
- Cvetković R.S. & Perry C.M., 2006. Rituximab. Drugs. 66:791-820.
- Freeman C. L. & Sehn L. H., 2018. A tale of two antibodies: obinutuzumab versus rituximab. Br. J. Haematol. 182(1):29-45.
- Soe Z. N. & Allsup D., 2017. The use of ofatumumab in the treatment of B-cell malignancies. Future Oncol. 13(29):2611-2628.
- Maglioco A. et al., 2017. B cells inhibit the antitumor immunity against an established murine fibrosarcoma. Oncology letters. 13(5):3225-3232.